Did a Permissive Scientific Culture Encourage the ‘CRISPR babies’ experiment?
By Donna Dickenson, Marcy Darnovsky,
Nature Biotechnology
| 03. 15. 2019
To the Editor — The claim last November by He Jiankui to have engineered the first CRISPR-edited babies has ignited voluble condemnation from scientists worldwide. What, then, made this rogue researcher think that his ‘achievement’ would be welcomed? One possible factor is that He claimed that he was influenced by the words and actions of key US and UK scientists. He attended and was an invited speaker at several meetings about gene editing, including several focused on the ethical acceptability of human germline modification1. And he explicitly cited the 2017 US National Academies of Science report as support for what he did2.
The Nuffield Council on Bioethics in the UK also issued a report in July 20183. Notably, it concludes that germline genome editing could be permissible under certain circumstances. More strongly, it moves beyond the merely permissible to the ethically obligatory, saying in its final section (paragraph 5.2) that “there are moral reasons to continue with the present lines of research and to secure the conditions under which heritable genome editing would be...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...